Diabetes
More than a dozen semaglutide generics hit the Indian market at sharp discounts post LOE for Novo Nordisk’s GLP-1 RA molecule, setting the stage for a high-octane battle in the diabetes and obesity segment. Can Novo hold steady amid the avalanche and what are KOLs looking for?
Natco has announced a 90% difference in the price of its semaglutide generic in multi-dose vials versus originator Novo Nordisk’s Ozempic pen ahead of launch tomorrow, as Novo’s patents on the product expire today. Its pen will be 70% cheaper.
Natco has announced a 90% difference in the price of its semaglutide generic in multi-dose vials versus originator Novo Nordisk’s Ozempic pen ahead of launch tomorrow as Novo’s patents on the product expire today. Its pen will be 70% cheaper.
Zydus’s investment in a differentiated drug-device combination for semaglutide has led to a win-win GLP-1 co-marketing deal with Lupin, even as the Indian drug regulator keeps a watch on advertising activities.
India issues firm advisory on promos for obesity and metabolic disorders therapies ahead of loss of exclusivity for semaglutide later this week, with 50-plus generic brands seen in the wings for a share of the pie. Will Eli Lilly and Novo Nordisk have to tweak their multimedia campaigns?
Zydus’s investment in a differentiated drug-device combination for semaglutide has led to a win-win GLP-1 co-marketing deal with Lupin even as the Indian drug regulator keeps a watch on advertising activities
India issues firm advisory on promos for obesity and metabolic disorders therapies ahead of loss of exclusivity for semaglutide later this week, with 50-plus generic brands seen in the wings for a share of the pie. Will Eli Lilly and Novo Nordisk have to tweak their multimedia campaigns?
The mineralocorticoid receptor antagonist, which will be a key driver at the German group in the post-Xarelto world, significantly delayed kidney disease progression in non-diabetic patients in another successful late-stage trial.
India issues firm advisory on promos for obesity and metabolic disorders therapies ahead of loss of exclusivity for semaglutide later this week, with 50-plus generic brands seen in the wings for a share of the pie. Will Eli Lilly and Novo Nordisk have to tweak their multimedia campaigns?
Sandoz says GLP-1s represent a long-term growth opportunity but warns the off-patent market will take time to develop, with early launches potentially coming in Canada and Brazil as the company tests supply dynamics and regulatory timelines.
Aspen Pharmacare is targeting early launches of generic semaglutide as patents begin to expire, aiming to be among the first entrants in Canada’s emerging market for GLP-1 rivals and using the approval as a springboard into emerging markets.
SamChunDang Pharmaceutical has penned an exclusive licensing and commercialization agreement covering generic versions of oral semaglutide products in the UK and additional European markets.